Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
about
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Status of adjuvant endocrine therapy for breast cancer.Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole.Adjuvant Systemic Therapy of Breast Cancer.Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupInterpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.Predicting benefit of endocrine therapy for early breast cancerOutcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.Switching between endocrine therapies for primary breast cancer: Frequency and timing in Australian clinical practice.Evaluating Markers for Guiding Treatment.Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients.Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
P2860
Q27002430-1C254451-C933-4413-89C1-5AF1EC4B6EA2Q28079118-5A8C7F4A-CCA9-4214-9814-D9D02B58C00CQ28085062-5FD722C6-28F5-4068-AA49-5FDCA28FAD79Q31075630-5BEBE933-25B1-4C01-BEEA-9EA220B8AC08Q33698446-DE5B7723-2BA0-476B-914E-02022A1E8952Q33739138-8965639B-BE03-4003-9883-C136E1E5E7CCQ33756969-3C15FA04-8651-42A9-9705-43B48DB19B0CQ34790668-799A643A-5119-4109-8C2E-F4B225C960F5Q35095595-677E9F8B-E8B0-4399-AA13-373392007915Q35552069-B7C82CE7-0F78-487F-AA06-F5B1B176F2AFQ35557992-832644AD-0F52-4BFB-A83A-83EC10F63BD0Q35607675-F24646F9-78EC-4E87-9600-6E1AB49F04F5Q35672166-D5E4C1C4-E36F-46C3-BC17-E98365041E40Q35842986-FACE58CA-7868-48E8-AAF0-138CB1555EFAQ35998828-F2DB64AE-B02E-46D1-BAEE-CF67BCFA658AQ36107130-46C30A96-5342-4DD1-AB59-1D9BDE20AE0EQ36271534-6E450B6D-A7AB-439C-A1E0-86C72C0157E4Q36316636-36E19470-55C8-4B7F-8AB4-823F45F5BF12Q36334705-74861D4B-DC5F-4D3F-961A-D1A2ECC2DE90Q37130142-64D14ECD-415B-412C-801D-C78E67E5E48CQ37130218-2E6C878D-014C-4259-8E0D-A1A462749071Q37202495-B2845558-ED51-4B33-B3E0-D3A62C901744Q37696677-75D8A745-3FCF-4390-8169-31CC48E79950Q38027578-BF6C166D-101E-41DC-A386-665633B1824AQ38028797-9099750C-9CBC-4E1D-917B-AACD80761DF5Q38272730-2B1DCAA9-7CF5-4F36-9196-970CE36A52F4Q38658655-270A065A-59CE-4482-A987-85F6824C888CQ38818289-2D94297D-704E-4F43-A4F5-B822916FB845Q39292860-E091619A-0EEC-456F-828F-5ECAA892C47DQ39755420-932160AF-2194-4113-9CA7-6F2B0DACAD45Q41558055-6F3954D8-C0BF-4833-80D0-C72331C3436EQ48030360-A65AB174-F62B-400B-848C-C85221E81C32
P2860
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@ast
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@en
type
label
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@ast
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@en
prefLabel
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@ast
Which patients benefit most fr ...... the BIG 1-98 randomized trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Which patients benefit most fr ...... the BIG 1-98 randomized trial
@en
P2093
A Goldhirsch
A S Coates
B A Gusterson
B B Rasmussen
B Thürlimann
BIG 1-98 Collaborative and International Breast Cancer Study Groups
G MacGrogan
H Mouridsen
P2860
P304
P356
10.1093/ANNONC/MDQ738
P577
2011-02-18T00:00:00Z